Cytokinetics (CYTK), Incorporated announced positive topline results from MAPLE-HCM, a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. MAPLE-HCM met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake from baseline to Week 24 for aficamten compared to metoprolol. The safety and tolerability profile of aficamten was favorable in comparison to metoprolol in MAPLE-HCM.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target lowered to $53 from $55 at Barclays
- Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
- Cytokinetics’ Earnings Call: Balancing Progress and Challenges
- Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
- Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating